Mitochondrial transplantation uses mitochondria isolated from the patient's own body to replace or augment native mitochondria damaged by ischemia reperfusion injury.
HIGHLIGHTS
Mitochondrial transplantation uses mitochondria isolated from the patient's own body to replace or augment native mitochondria damaged by ischemia reperfusion injury.
The transplanted mitochondria can be delivered to the myocardium by intra-coronary injection.
Intracoronary injection of mitochondria is safe and has no effect on coronary patency.
Intracoronary injection of mitochondria provides for the rapid uptake and specific biodistribution of mitochondria throughout the heart. Intracoronary mitochondrial transplantation is efficacious and provides for enhanced post-ischemic myocardial function, improved coronary blood flow and reduction of infarct size.
SUMMARY
Mitochondrial dysfunction is the determinant insult of ischemia-reperfusion injury. Autologous mitochondrial transplantation involves supplying one's healthy mitochondria to the ischemic region harboring damaged mitochondria. The authors used in vivo swine to show that mitochondrial transplantation in the heart by intracoronary delivery is safe, with specific distribution to the heart, and results in significant increase in coronary blood flow, which requires intact mitochondrial viability, adenosine triphosphate production, and, in part, the activation of vascular K IR channels. Intracoronary mitochondrial delivery after temporary regional ischemia significantly improved myocardial function, perfusion, and infarct size. The authors concluded that intracoronary delivery of mitochondria is safe and efficacious therapy for myocardial ischemia-reperfusion injury. 
I
schemic heart disease is one of the leading causes of global morbidity and mortality (1) . Mitochondrial damage is the principal pathogenesis of myocardial ischemia-reperfusion injury leading to cardiomyocyte death and contractile failure (2-7).
We have previously developed a novel therapy, autologous mitochondrial transplantation, in which viable, respiration-competent mitochondria from nonischemic tissue from the patient's own body are isolated and then transplanted into the ischemic myocardium to ameliorate the effects of mitochondrial damage experienced by the ischemic region. The therapeutic efficacy of mitochondrial transplantation was demonstrated in a series of animal studies (8) (9) (10) (11) (12) (13) (14) and showed promise in a recent human application (15) . In both animals and humans, post-ischemic transplantation of healthy mitochondria by direct injection into the myocardium results in significant improvements of contractile function and tissue viability of the injured myocardium.
The transplanted mitochondria are readily internalized by cardiac cells (11) by actin-dependent endocytosis (12) , with rapid cytosolic transition and fusion with the endogenous mitochondrial network (13) . The transplanted mitochondria act to increase myocardial adenosine triphosphate (ATP) levels, upregulate proteomic pathways for mitochondrial function, upregulate myoprotective cytokines, and replace damaged mitochondrial deoxyribonucleic acid (8) (9) (10) .
Although mitochondrial transplantation by direct tissue injection of donor mitochondria is therapeutically effective, it harbors limitations in that multiple injections and physical manipulations of the heart are necessary for adequate distribution of mitochondria throughout the heart. Open access to the heart is also required, which significantly limits the potential patient population who could undergo mitochondrial transplantation.
Minimally invasive, intracoronary delivery of mitochondria can avoid these drawbacks and disseminate mitochondria to the entire region that was infused, allowing an entry for whole-organ mitochondrial therapy. Previous studies using an isolated perfused heart model have demonstrated that intracoronary delivery of mitochondria results in rapid uptake and global distribution of the transplanted mitochondria (11) . However, preclinical in vivo evaluation of the biodistribution, safety, and efficacy of intracoronary delivery of mitochondria is imperative for clinical translation and the expansion of therapeutic applications.
In the present report, we investigated the biodistribution and the safety of a catheter-based, intracoronary mitochondrial transplantation and evaluated the therapeutic efficacy in treating regional myocardial ischemia-reperfusion injury in the clinically relevant in vivo swine model.
METHODS

All procedures conformed to institutional guidelines
for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital.
EXPERIMENTAL DESIGN. A total of 57 adult female Yorkshire swine (45.0 AE 5.5 kg) were used. This study was conducted in 3 phases. In the first phase, the safety profile and biodistribution of mitochondria by intracoronary delivery was determined in the nonischemic swine. In the second phase, based on the first-phase finding of the increase in coronary blood flow (CBF) from intracoronary infusion of mitochondria, the mechanism of mitochondria-induced increase in CBF was investigated. Finally, in the third phase, the efficacy of intracoronary mitochondrial transplantation in providing cardioprotection after regional myocardial ischemia was evaluated. during 5 s, followed by a 5-ml saline flush. Two pieces of muscle were harvested from the pectoralis major muscle of each animal with a 6-mm biopsy punch and immediately used for mitochondrial isolation. Autologous mitochondria were isolated and mitochondrial ATP content was measured as previously described (8, 9, 16) . 
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AREA AT RISK AND INFARCT SIZE. Area at risk and infarct size were determined with tetrazolium chloride staining and planimetry analysis (7-9). not affect heart rate, mean arterial pressure, or
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shortening, showed a modest increase on injection of mitochondria into the vasoconstricted LCA (11.3% AE 1.5% vs. 8.5% AE 0.8%; p ¼ 0.017) ( Figure 4G ). Shin et al.
into the LCA (n ¼ 5). The sizes of the microbeads were chosen to exceed the size ranges of mitochondria (0.5-1.0 mm) (Supplemental Figure S1 ). Intracoronary injection of 3-mm microbeads had no effect on hemodynamics or LV function (Supplemental Figure S2 ). In contrast, 10-and 150-mm microbeads, which significantly exceed the size of the injected mitochondria, resulted in significant coronary 
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occlusions and myocardial contractile failure (Supplemental Figure S2 ). ( Figure 5A ). Intracoronary injection of HeLa mitochondria, which are capable of oxidative phosphorylation, increased CBF from 24.6 AE 2.9 ml/min to 79.7 AE 8.1 ml/min (n ¼ 6; p < 0.001) ( Figure 5A ). In ATP ¼ adenosine triphosphate; other abbreviations as in Figure 3 . was injected alone (p < 0.001).
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S i g n a l i n g p a t h w a y s o f c o r o n a r y v a s o d i l a t i o n .
Mitochondria-induced increase in CBF was unaf- 
DISCUSSION
In our previous studies, transplantation of mitochondria was performed by direct tissue injection with a 28-gauge-needle syringe (6, (8) (9) (10) 14, 15) . This technique allows specific delivery of the donor mitochondria to a localized area of the myocardium.
Although effective, it requires open-heart access, potential manipulation of the heart, and multiple injections. We have previously reported the histologic quantification of radioactive, iron oxidelabeled, human mitochondria transplanted to isolated perfused rabbit hearts through intracoronary delivery (11) . Similar to our present findings, positron emission tomographic imaging of these isolated hearts showed global distribution of radioactive signal throughout the entire organ, whereas histologic analysis showed mitochondria within blood vessels (25.7%), cardiomyocytes (23.6%), and the
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Shin et al. Shin et al. or mitochondria. * p < 0.05 and † p < 0.001 between the 2 groups. Abbreviations as in Figure 2 . shortening, and increased total tissue ATP content in the area at risk (6, 8, 9) .
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In the present study, we focused our attention on demonstrating the systemic distribution of mitochondria when delivered via the coronary arteries.
We first evaluated the uptake and biodistribution of mitochondria by intracoronary delivery, using 18 Frhodamine-6G, which specifically labels actively respiring mitochondria (16) . Positron emission tomographic imaging demonstrated that intracoronary delivery distributed mitochondria specific to the The mechanisms of vascular extravasation of mitochondria are beyond the scope of the current investigation and remain to be fully elucidated.
However, the rapidity of mitochondria transport to cardiac cells is likely to involve mechanisms similar to those involved in bacterial or viral uptake (28) (29) (30) .
Support for such pathways may be seen in our studies
showing the rapid uptake of mitochondria, using 18 Our results suggest that ATP is at least partly responsible for mitochondria-induced hyperemia because the increase in CBF was achievable only through the delivery of intact, respiration-competent mitochondria. ATP has been reported to be a potent dilator of coronary circulation (38) (39) (40) . This is further corroborated by our finding that mitochondria- Although the full mechanism remains to be elucidated, the biochemical milieu of the ischemic heart is markedly different from that of the normal heart. We 
